ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Kyowa Hakko Kirin Co., Ltd.

  • 1,950.00 JPY
  • -7.00
  • -0.36%
  • Japan
    Jun 26, 2019
  • Ticker
    TKS(4151)
  • Prev. close
    1,957
  • Market cap (JPY)
    1,056.78B
  • Market cap (USD)
    9,813.62M
  • Shares
    540M

Business Summary

Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2018 JPYUSD
Revenue346,531M3,137.65M
Gross Profit218,840M1,981.47M
Operating income58,791M532.32M
Income before tax73,438M664.94M
Net income54,414M492.68M
EBITDA81,012M733.51M
Diluted EPS99.290.89
Dividends Per Share350.31
Total Assets741,982M6,762.81M
Total liabilities92,361M841.82M
Total equity649,621M5,920.98M
Operating cash flow56,181M508.68M
Currency in JPYCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 333,446M 364,316M 347,956M 353,380M 346,531M
Gross Profit 183,475M 201,072M 204,610M 215,972M 218,840M
Operating income 36,173M 43,765M 51,468M 62,209M 58,791M
Income before tax 27,245M 41,400M 42,877M 55,849M 73,438M
Net income 15,898M 29,774M 30,450M 42,899M 54,414M
EBITDA 72,884M 80,324M 75,252M 84,241M 81,012M
Diluted EPS 29.02 54.36 55.59 78.30 99.29
Dividends Per Share 25 25 25 27 35
Total Assets 719,135M 720,764M 683,801M 708,295M 741,982M
Total liabilities 113,767M 105,906M 106,766M 92,268M 92,361M
Total equity 605,368M 614,858M 577,036M 616,028M 649,621M
Operating cash flow 19,377M 66,526M 66,881M 64,902M 56,181M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 3,150.17M 3,009.26M 3,202.27M 3,151.41M 3,137.65M
Gross Profit 1,733.34M 1,660.86M 1,883.04M 1,926.02M 1,981.47M
Operating income 341.73M 361.50M 473.66M 554.77M 532.32M
Income before tax 257.39M 341.96M 394.60M 498.05M 664.94M
Net income 150.19M 245.93M 280.23M 382.57M 492.68M
EBITDA 688.55M 663.47M 692.55M 751.25M 733.51M
Diluted EPS 0.27 0.44 0.51 0.69 0.89
Dividends Per Share 0.23 0.20 0.23 0.24 0.31
Total Assets 5,998.04M 5,991.63M 5,862.74M 6,287.57M 6,762.81M
Total liabilities 948.88M 880.38M 915.38M 819.06M 841.82M
Total equity 5,049.15M 5,111.25M 4,947.36M 5,468.51M 5,920.98M
Operating cash flow 183.06M 549.50M 615.51M 578.79M 508.68M

Valuation Measures

Dec 2018
PER20.89
ROA7.50%
ROE8.59%
Operating margin16.96%
Profit margin15.70%

Key executives

  • Chairman & Chief Executive Officer: Nobuo Hanai
  • President, COO & Representative Director: Masashi Miyamoto
  • Executive Officer, GM-Research & Development: Mitsuo Satoh
  • Representative Director & Executive Vice President: Yutaka Osawa
  • Executive Officer & General Manager-Sales: Hiroshi Sugitani

Shareholders

  • Kirin Holdings Co., Ltd. (53.4%)
  • Nomura Asset Management Co., Ltd. (3.2%)
  • Japan Agricultural Cooperatives Group (1.9%)
  • Nikko Asset Management Co., Ltd. (1.4%)
  • Daiwa Asset Management Co. Ltd. (1.3%)
  • Mizuho Bank Pension Fund (1.2%)
  • The Vanguard Group, Inc. (1.2%)
  • Wellington Management Co. LLP (1.1%)
  • Norges Bank Investment Management (0.7%)
  • BlackRock Fund Advisors (0.7%)

Contact Details

  • Website:http://www.kyowa-kirin.co.jp
  • Address: Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Tokyo, 100-0004, Japan
  • Phone: +81.3.5205.7200

Related Companies

  • Kyowa Kirin GmbH
  • Strakan International SARL
  • Kyowa Kirin Plus Co. Ltd.
  • Kyowa Hakko Bio Co. Ltd. (Beijing)
  • Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
  • Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
  • Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
  • Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
  • Kyowa Hakko Kirin (Taiwan) Co. Ltd.
  • Kyowa Hakko Kirin (Singapore) Pte Ltd.
  • Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin (Thailand) Co. Ltd.
  • ProStrakan SRL
  • Kyowa Hakko Kirin America, Inc.
  • Kyowa Hakko Kirin Korea Co., Ltd.
  • Kyowa Hakko Kirin Employee Stock Owner Ship Plan
  • Kyowa Hakko Bio Italia SRL
  • Zenmi Foods, Inc.
  • Chiyoda Kaihatsu Co., Ltd.
  • Kyowa Hakko Kirin California, Inc.
  • Kyowa Kirin International Plc
  • BioWa, Inc.

Competitors

  • Biocon Limited
  • Coherus BioSciences, Inc.
  • FibroGen, Inc.
  • arGEN-X SE
  • Genexine, Inc.
  • Miragen Therapeutics, Inc.
  • Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A
  • Tetralogic Pharmaceuticals Corporation
  • Insys Therapeutics, Inc.
  • Seattle Genetics, Inc.
  • Dermira Inc
  • Heron Therapeutics Inc
  • Portola Pharmaceuticals, Inc.
Last Updated on 26 Jun, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media